Suscribirse

Indigo naturalis (Qing dai) for inflammatory bowel disease: A systematic review and meta-analysis - 10/01/24

Doi : 10.1016/j.clinre.2023.102250 
Rinkalben Kakdiya a, 1, Daya Krishna Jha b, 1, Arup Choudhury c, Anuraag Jena d, Vishal Sharma e,
a Surat Institute of Digestive Science, Surat, Gujarat, India 
b Department of Gastroenterology, Army Hospital R and R, Delhi, India 
c Department of Medicine, Nagaon Medical College Hospital, Assam, India 
d Department of Gastroenterology, Institute of Medical Sciences and SUM Hospital, Bhubaneswar, India 
e Department of Gastroenterology, Postgraduate Institute of Medical Education and Research, Chandigarh, India 

Corresponding author.

Highlights

•What is already known on this subject?.
There is an unmet need for new treatment options in the armamentarium of UC, with differing mechanisms of action and a better safety profile. Indigo naturalis is a traditional therapy reported to be useful in inflammatory bowel disease (IBD).
•What are the new findings?.
Indigo naturalis is effective in the treatment of ulcerative colitis and the systematic review suggests that almost 80 % of patients receiving the drug have a clinical response with a rare adverse event of pulmonary hypertension.
•How might it impact on clinical practice in the foreseeable future?.
Indigo naturalis is useful in the treatment of ulcerative colitis and provides clinicians with one more relatively cheap option.

El texto completo de este artículo está disponible en PDF.

Abstract

Background

Indigo naturalis (Qing dai) is a traditional therapy reported to be useful in inflammatory bowel disease (IBD), especially for ulcerative colitis. We performed a systematic review of its efficacy and safety in IBD.

Methods

Electronic databases (Pubmed, Embase, and Scopus) were searched on 4th March 2023 to identify reports about the use of indigo naturalis in IBD. We extracted data with respect to clinical response, remission, endoscopic and histological responses, and adverse events with the use of indigo naturalis in IBD. Pooled clinical response rates and remission rates were calculated. The quality of studies was assessed using Joanna-Briggs tools.

Results

Nine studies reporting on 299 patients were included. The pooled clinical response rate was 0.796 (95 %CI, 0.7465–0.8379, I2=0), and the clinical remission rate in ulcerative colitis was 0.668 (0.488- 0.809, I2=85.2 %). The pooled relative risk of clinical response was higher in the indigo naturalis group as compared to placebo in the two randomized trials [3.82 (2.04; 7.14, I2=0)]. Except for one reversible pulmonary arterial hypertension case, most reported adverse effects were mild. The endoscopic and histological responses, when reported, suggested that indigo naturalis is effective for ulcerative colitis. The limitations of the systematic review included a small number of randomized studies, reports only from East Asia and a relatively small number of patients, especially for Crohn's disease.

Conclusion

Indigo naturalis is effective in the treatment of ulcerative colitis. Future studies should evaluate the comparative efficacy with other drugs.

El texto completo de este artículo está disponible en PDF.

Keywords : Indigo naturalis, Ulcerative colitis, Inflammatory bowel disease, Crohn's disease, Pulmonary artery hypertension, Complementary and alternative therapy


Esquema


© 2023  Elsevier Masson SAS. Reservados todos los derechos.
Añadir a mi biblioteca Eliminar de mi biblioteca Imprimir
Exportación

    Exportación citas

  • Fichero

  • Contenido

Vol 48 - N° 1

Artículo 102250- janvier 2024 Regresar al número
Artículo precedente Artículo precedente
  • Clinical factors associated with illness perception, worry and mental health in sclerosing cholangitis: A single centre prospective study
  • Jeremy S. Nayagam, Wafaa Ahmed, Matthew Farrant, Jamie Jefferies, Vanessa Boshell, Anna Simpson, Deepak Joshi
| Artículo siguiente Artículo siguiente
  • Gastric microbiota in patients with gastric MALT lymphoma according to Helicobacter pylori infection
  • Antoine Martin, Marine Jauvain, Emma Bergsten, Vanessa Demontant, Philippe Lehours, Caroline Barau, Michael Levy, Christophe Rodriguez, Iradj Sobhani, Aurelien Amiot

Bienvenido a EM-consulte, la referencia de los profesionales de la salud.
El acceso al texto completo de este artículo requiere una suscripción.

¿Ya suscrito a @@106933@@ revista ?

Mi cuenta


Declaración CNIL

EM-CONSULTE.COM se declara a la CNIL, la declaración N º 1286925.

En virtud de la Ley N º 78-17 del 6 de enero de 1978, relativa a las computadoras, archivos y libertades, usted tiene el derecho de oposición (art.26 de la ley), el acceso (art.34 a 38 Ley), y correcta (artículo 36 de la ley) los datos que le conciernen. Por lo tanto, usted puede pedir que se corrija, complementado, clarificado, actualizado o suprimido información sobre usted que son inexactos, incompletos, engañosos, obsoletos o cuya recogida o de conservación o uso está prohibido.
La información personal sobre los visitantes de nuestro sitio, incluyendo su identidad, son confidenciales.
El jefe del sitio en el honor se compromete a respetar la confidencialidad de los requisitos legales aplicables en Francia y no de revelar dicha información a terceros.


Todo el contenido en este sitio: Copyright © 2024 Elsevier, sus licenciantes y colaboradores. Se reservan todos los derechos, incluidos los de minería de texto y datos, entrenamiento de IA y tecnologías similares. Para todo el contenido de acceso abierto, se aplican los términos de licencia de Creative Commons.